[Skip to Navigation]
Citations 0
Editor's Correspondence
March 22, 2010

Evaluating Enzyme Replacement Therapy in Fabry Disease—Reply

Author Affiliations

Author Affiliations: Department of Medicine, Baruch-Padeh Poria Medical Center, Tiberias, Israel.

Arch Intern Med. 2010;170(6):573-574. doi:10.1001/archinternmed.2010.43

In reply

Up to 60% of men with classic Fabry disease have cardiac abnormalities, including left ventricular hypertrophy, valvular dysfunction, and conduction abnormalities. Recent data suggest that left ventricular hypertrophy and systolic function improve after 12 months of ERT.1 Systolic function is usually preserved, but mild to moderate impairment of diastolic filling is a relatively common finding, representing probably the most important cause of dyspnea in patients with Fabry disease.2